|
April 2010 · Vol. 59, No. 04 Suppl: S3-S6
|
The dawn of a new era: Transforming our domestic response to hepatitis B & C
Release Date: April 1, 2010
Expiration Date: April 1, 2011
Estimated time to complete activity: 2.75 hours
Continue to article 
This activity is jointly sponsored by Postgraduate Institute for Medicine and HealthmattersCME. 
This activity is supported by independent educational grants provided by Bristol-Myers Squibb, Gilead Sciences Inc., and Vertex Pharmaceuticals.
 CME Information
How to obtain CME credit
Please go online to http://www.cmeuniversity.com and enter Course ID 7130 and complete the posttest, evaluation, and credit request in order to receive CME credit for “The dawn of a new era: Transforming our domestic response to hepatitis B & C.”
You will be able to print out your certificate upon notification that you have passed the posttest with a score of 70% or better.
Program Overview
Diseases associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) create a considerable burden on the nation’s health care system and pose many challenges in terms of effective identification, treatment, and patient management. Both chronic HBV and HCV infections are often asymptomatic, earning them reputations as silent killers. Many individuals are unaware that they are infected until they develop signs or symptoms of cirrhosis or liver cancer. As many as 2 million Americans are infected with HBV and 5 million are infected with HCV. Despite this large patient population, standards for virus prevention, screening, and clinical care are currently inadequate, resulting in a major unmet medical need.
Target Audience
This activity has been designed to meet the educational needs of physicians and physician assistants involved in the care of patients with chronic HBV and HCV.
Educational Objectives
After completing this activity, the participant should be better able to:
• Describe the need for a coordinated national response to chronic HBV and HCV
• Identify improved strategies for the screening, diagnosis, treatment, and care of people with HBV or HCV
• Outline the most recent recommendations from the Centers for Disease Control and Prevention on screening and managing HBV and HCV infections in clinical practice
• Differentiate among available therapeutic agents for HBV and HCV to optimize treatment
• Identify factors that might affect the response to treatment of infected individuals
• Describe specific treatment and management strategies in order to delay the onset of liver disease
• Identify the ethnic, racial, and socioeconomic disparities in chronic liver disease, including hepatocellular carcinoma, and screening
• Specify strategies to overcome ethnic, racial, and socioeconomic disparities in the screening and diagnosis of patients with chronic liver disease
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and HealthmattersCME. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
PIM designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
PIM assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
PIM planners and managers—Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; and Jan Schultz, RN, MSN, CCMEP—hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
HealthmattersCME planners and manager—James Murphy and Yelena Lyustikman—hereby state that they or their spouse/ life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, HealthmattersCME, Bristol-Myers Squibb, Gilead Sciences Inc., and Vertex Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, HealthmattersCME, Bristol-Myers Squibb, Gilead Sciences Inc., and Vertex Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period April 1, 2010, through April 1, 2011, participants must (1) read the learning objectives and faculty disclosures; (2) study the educational activity; (3) complete the posttest by going to http://www.cmeuniversity.com, entering Course ID 7130, and recording the best answer to each question; and (4) complete the evaluation form and credit request.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Information
Harvey J. Alter, MD, MACP
Dr Alter has no real or apparent conflicts of interest to report.
Miriam J. Alter, PhD
Dr Alter has no real or apparent conflicts of interest to report.
Janelle Tangonan Anderson, MA
Ms Anderson has no real or apparent conflicts of interest to report.
William B. Baine, MD
Dr Baine has no real or apparent conflicts of interest to report.
Joan M. Block, RN, BSN
Ms Block has no real or apparent conflicts of interest to report.
Jeffrey B. Caballero, MPH
Mr Caballero has no real or apparent conflicts of interest to report.
Denton Chase
Mr Chase has no real or apparent conflicts of interest to report.
Laura W. Cheever, MD, ScM
Dr Cheever has no real or apparent conflicts of interest to report.
Edward A. Chow, MD
Dr Chow has no real or apparent conflicts of interest to report.
Corinna Dan, RN, MPH
Ms Dan has no real or apparent conflicts of interest to report.
Lynda Dee, JD
DSMB: Merck, Schering-Plough
Adrian M. Di Bisceglie, MD, FACP
Consultant: Abbott, Anadys, Bristol-Myers Squibb, GlobeImmune, Inc, Idenix, Novartis, Pharmasset, Roche Pharmaceuticals, Schering-Plough, Vertex Pharmaceuticals
Grant/Research Support: Bristol-Myers Squibb, Gilead Sciences Inc., GlobeImmune, Inc, Idenix, Pharmasset, Roche Pharmaceuticals, Vertex Pharmaceuticals
Speakers Bureau: Novartis
Jules L. Dienstag, MD
Consultant: Abbott Molecular, Boehringer Ingelheim, Bristol-Myers Squibb, Genzyme, Human Genome Sciences, Medtronic, Schering-Plough Research Institute
Grant/Research Support: NIDDK, Vertex
Ownership Interest: Options: Achillion, Metabasis, Nucleonics
Son T. Do, MD
Consultant: Asian Health Foundation, Bristol-Myers Squibb, Gilead Sciences Inc.
Grant/Research Support: Bristol-Myers Squibb, Gilead Sciences Inc.
Speakers Bureau: Abbott, Centocor
Edward C. Doo, MD
Dr Doo has no real or apparent conflicts of interest to report.
Brian R. Edlin, MD
Dr Edlin has no real or apparent conflicts of interest to report.
Hashem B. El-Serag, MD, MPH
Dr El-Serag has no real or apparent conflicts of interest to report.
Ted Fang
Mr Fang has no real or apparent conflicts of interest to report.
Garth N. Graham, MD, MPH
Dr Graham has no real or apparent conflicts of interest to report.
Charles D. Howell, MD
Consultant: Abbott, Roche Pharmaceuticals, Vertex Pharmaceuticals
Speakers Bureau: Vertex Pharmaceuticals
Dale J. Hu, MD, MPH
Dr Hu has no real or apparent conflicts of interest to report.
Ira M. Jacobson, MD
Consultant: Abbott, Anadys, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences Inc., GlobeImmune, Inc, Human Genome Sciences, Idenix, Intermune, Merck, Novartis, Pfizer, Pharmasset, Progenics, Roche Pharmaceuticals, Sanofi-Aventis, Schering-Plough, Tibotec, Vertex Pharmaceuticals, Virochem, Zymogenetics
Grant/Research Support: Anadys, Boehringer Ingelheim, Gilead Sciences Inc., GlobeImmune, Inc, Human Genome Sciences, Idenix, Intarcia, Merck, Novartis, Pharmasset, Roche Pharmaceuticals, Romark, Schering-Plough, Tibotec, Valeant, Vertex Pharmaceuticals
Speakers Bureau: Bristol-Myers Squibb, Gilead Sciences Inc., Novartis, Schering-Plough
Fasiha Kanwal, MD, MSHS
Dr Kanwal has no real or apparent conflicts of interest to report.
W. Ray Kim, MD
Consultant: Bristol-Myers Squibb, Gilead Sciences Inc., Roche Pharmaceuticals
Grant/Research Support: Romark
T. Jake Liang, MD
Dr Liang has no real or apparent conflicts of interest to report.
Anna S. F. Lok, MD, FRCP
Consultant: Bristol-Myers Squibb, Gilead Sciences Inc.
Grant/ResearchSupport: Bristol-Myers Squibb, Gilead Sciences Inc.
Willis C. Maddrey, MD, MACP
DSMB: Intermune, Johnson & Johnson, Novartis, Pfizer, Roche Pharmaceuticals, Schering-Plough
M. Michele Manos, PhD, MPH, DVM
Grant/Research Support: Gilead Sciences Inc., Vertex Pharmaceuticals
Katherine A. McGlynn, PhD, MPH
Dr McGlynn has no real or apparent conflicts of interest to report.
Jeffrey S. Murray, MD, MPH
Dr Murray has no real or apparent conflicts of interest to report.
Robert P. Perrillo, MD
Consultant: Bristol-Myers Squibb
Speakers Bureau: Bristol-Myers Squibb
Marion G. Peters, MD, FRACP
Consultant: Clinical Care Options, Genentech, Pharmasset
Salary: Dr Peters’ spouse receives a salary from Genentech.
David B. Ross, MD, PhD
Dr Ross has no real or apparent conflicts of interest to report.
Martha Saly
Ms Saly has no real or apparent conflicts of interest to report.
Lorren Sandt
Ms Sandt has no real or apparent conflicts of interest to report.
Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF
Consultant: Bayer, Bristol-Myers Squibb, Conatus, Evivar, Gilead Sciences Inc., GlobeImmune, Inc, Johnson & Johnson, Merck, Novartis/Idenix, Roche Molecular, Schering-Plough, Vertex Pharmaceuticals
DSMB: Daiichi-Sankyo, Johnson & Johnson, Pfizer, Salix Pharmaceuticals, Schering-Plough, Wyeth
Grant/Research Support: Abbott, Bristol-Myers Squibb, Conatus, Debiopharm, Gilead Sciences Inc., GlobeImmune, Inc, Idenix, Merck, Novartis/Idenix, Roche Diagnostics, Roche Molecular, Roche Pharmaceuticals, Salix Pharmaceuticals, Inc, Sanofi-Aventis, Schering-Plough, Vertex Pharmaceuticals, Wyeth
Vernon K. Smith, PhD
Dr Smith has no real or apparent conflicts of interest to report.
Samuel So, MD, FACS
Dr So has no real or apparent conflicts of interest to report.
Tracy Swan
Ms Swan has no real or apparent conflicts of interest to report.
Litjen (L. J.) Tan, MS, PhD
Dr Tan has no real or apparent conflicts of interest to report.
Chris Taylor
Mr Taylor has no real or apparent conflicts of interest to report.
Norah A. Terrault, MD, MPH
Consultant: Bristol-Myers Squibb, Roche Pharmaceuticals, Schering-Plough, Siemens Diagnostics
Grant Research/Support: Eisai, Human Genome Sciences, Roche Pharmaceuticals, Vertex Pharmaceuticals
Thelma King Thiel, RN
Ms Thiel has no real or apparent conflicts of interest to report.
David L. Thomas, MD, MPH
Dr Thomas has no real or apparent conflicts of interest to report.
Ronald O. Valdiserri, MD, MPH
Dr Valdiserri has no real or apparent conflicts of interest to report.
Su Wang, MD, MPH
Dr Wang has no real or apparent conflicts of interest to report.
John W. Ward, MD
Dr Ward has no real or apparent conflicts of interest to report.
Cindy Weinbaum, MD, MPH
Dr Weinbaum has no real or apparent conflicts of interest to report.
John B. Wong, MD
Dr Wong has no real or apparent conflicts of interest to report.
Lester N. Wright, MD, MPH
Dr Wright has no real or apparent conflicts of interest to report.
Janet Zola, MPH
Ms Zola has no real or apparent conflicts of interest to report.
The Journal of Family Practice ©2010 Quadrant Healthcom Inc.
|
